Archive:
Diabetic polyneuropathy (DPN) is associated with significantly increased healthcare costs and thus an economic burden on society and the healthcare system (Happich et al. 2008; Khdour 2020; Shillo et al. 2019). A high number of hospital stays, need for care, incapacity to work as well as follow-up costs of DPN (e.g. amputations) and an overall greater use of healthcare resources are responsible for the higher medical costs (Sadosky et al. 2015; Schroeter/Hartung 2005; Ziegler 2020) and illustrate this Burden on patients suffering from DPN. The costs tend to increase as the burden of illness increases (Happich et al. 2008).
28.11.2022
In a current representative survey by the Federal Center for Health Education (BZgA) on infection protection, 81% of those surveyed said they were supporters of vaccination. The proportion of those who have a positive attitude towards vaccinations has increased by 22 percentage points since 2012. In comparison, 15% are at least partially more critical of vaccinations and 4% are (more) negative (Seefeld et al. 2022). Despite the high proportion of vaccination supporters, the political requirements according to §132e SGB V to increase the vaccination rates for the vaccinations recommended by the Standing Vaccination Commission (STIKO) have not been achieved in recent years. For example, the nationwide average vaccination rate for the first measles vaccination in children aged 15 months is currently 85.8%. This means that almost all districts are missing the target of 95% for this age group set in the National Measles Action Plan. The potential of the HPV vaccination (vaccination against human papilloma viruses) for girls and boys is still far from exhausted, despite slightly increasing vaccination rates. According to the KV vaccination surveillance, 47.2% of 15-year-old girls were fully vaccinated in 2019. The vaccination rates varied greatly regionally between 37.7% in Bremen and 66.9% in Saxony-Anhalt.
28.11.2022
Die digitale Transformation in der Medizin versetzt uns in die Lage, immer größere und komplexere Datenmengen in verwertbares Wissen zu verwandeln. Die klassische medizinische Evidenzgenerierung wird dadurch zunehmend ergänzt oder sogar teilweise ersetzt durch versorgungsnahe Daten bzw. Real-World-Data (RWD). Damit einher geht die Chance, Arzneimittelforschung besser, effizienter, sicherer und schneller zu gestalten. Erkenntnisse können schneller in die Versorgung und klinische Entscheidungsprozesse einfließen. Um diese Chance zu nutzen, gilt es, Althergebrachtes allmählich loszulassen.
28.11.2022
On the past, present and future of the use of GKV routine data for health care research: Access and availability are of course particularly important for health care research, but also for many other parties who work in and for the health care system. The “Data Usage Act” (DNG) passed by the previous government (Federal Ministry of Justice 2021) got the ball rolling in this regard, including introducing the term “research data”1, but ultimately raised more questions than it resulted in any useful regulations.
28.11.2022
Organizational tensions refer to conflicts that arise from opposing, sometimes contradictory views and requirements in an organization (Smith/Lewis 2011, 2022; Putnam et al. 2016; Farjoun 2017). In situations in which different development directions and perspectives come together, these tensions become noticeable. The contradictions underlying the tensions in an organization can vary in strength and range from simple discrepancies and differing views, to dilemmas, i.e. opposing options for action, to irresolvable contradictions or paradoxes.
28.11.2022
On July 27, 2022, the Federal Cabinet passed the draft of a law for the financial stabilization of statutory health insurance (GKV Financial Stabilization Act), which - after being submitted to the parliamentary procedure - was passed by the Bundestag on October 20, 2022 and finalized by the Bundesrat on October 28, 2022 was approved. Dierk Neugebauer, Vice President Market Access at Bristol-Myers Squibb GmbH & Co. KGaA, explained at the online press conference “Oncology: Rethinking the fight against cancer” what effects the law could have on Germany as a research location.
28.11.2022
Prof. Dr. Franz Porzsolt, der seit dem Jahr 1994 in vielen wissenschaftlichen Publikationen seinen Begriff von klinischer Ökonomik zu prägen versucht und zudem als einer der Erfinder der „Pragmatic Controlled Trials“ gelten kann, gilt ebenso als ein eher unbequemer Zwischenrufer, der sich immer wieder an Glaubenssätzen und Grundfesten von Forschung und Medizin abarbeitet. So auch an der Versorgungsforschung, der er sich – als klinischer Forscher und versorgender Onkologe – seit vielen Jahren verbunden fühlt. Er begreift diese Wissenschaftsrichtung „als Königsdisziplin aller Forschungsmethoden im Gesundheitssystem“, die es immer mit hoch komplexen Systemem zu tun habe und sich nicht nur mit einem Priorisierungskatalog, sondern auch einem grundlegenden Fragebogenkonzept auseinandersetzen muss.
28.11.2022
In der Online-Pressekonferenz anlässlich der 55. Jahrestagung der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie e.V. (DGTI) warnte Univ.-Prof. Dr. med. Hermann Eichler, Direktor des Instituts für Klinische Hämostaseologie und Transfusionsmedizin, Universität und Universitätsklinikum des Saarlandes, vor einem Blut-Notstand angesichts zu wenig Blutspenden und leerer Blutbanken. Die Frage „Gefährdet die Corona-Pandemie die transfusionsmedizinische Versorgung? beantworte Eichler mit einem eindeutigem Ja.
30.09.2022
In the big summer interview on the occasion of the 10th anniversary as impartial chairman of the Federal Joint Committee, Prof. Josef Hecken spoke about AMNOG developments, the future EU HTA assessment and changes in the benefit assessment process due to the current Statutory Health Insurance Financial Stabilization Act - which can be found in the recently published issue Issue of “Market Access & Health Policy”, the sister magazine of “Monitor Healthcare Research”. In this interview part, Hecken describes his successes, but also what, in his opinion, didn't go so well or went wrong. He also formulates a clear maxim for action in health services research, which would significantly increase the impact of this field of science.
22.09.2022
Medidata, a Dassault Systèmes company, recently announced the publication of the report “European Industry Research Report: The Future of Clinical Trials”. The report is based on new independent research that includes insights from 400 clinical trials executives from Germany, Switzerland, France and the United Kingdom. The aim of the survey was to gain a deeper understanding of how clinical trials have changed in the past two years, how new technologies play a role and what the future could bring in this area.